Business
GSK and iTeos announce collaboration for EOS-448
GSK and iTeos announce collaboration for EOS-448.
About this update from Gsk Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7779B\n GlaxoSmithKline PLC\n 14 June 2021\n \n \n \n \n 14 June 2021, London UK & Gosselies Belgium\n \n \n \n \n \n GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations\n \n \n \n \n \n · \n EOS-448 is currently in phase I for advanced solid tumours with a randomised PD-1 combination study planned for 2022\n \n \n · \n iTeos to receive a $625 million upfront payment in addition to potential milestones, and royalty payments on ex-US sales\n \n \n · \n GSK and iTeos will co-commercialise and share profits in the US\n \n \n · \n GSK now has the leading \n portfolio of antibodies targeting the CD226 axis - a key target for next-generation immuno-oncology therapies\n \n \n \n \n \n \n \n \n GlaxoSmithKline plc (LSE/NYSE: GSK) and iTeos Therapeutics (NASD: ITOS) today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomised clinical trial. With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG.\n \n \n \n \n \n \n Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said:\n \n \"Immuno-oncology has transformed cancer care but unfortunately less than 30 percent of patients respond to treatment with the current leading immune checkpoint inhibitors. Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer. We are excited to collaborate with the team at iTeos and together we can play a leading role in the next generation of immuno-oncology therapies.\"\n \n \n \n \n \n Since GSK validated the role of CD226 axis targets as important in oncology, it has been strategically building a carefully constructed set of assets to target this network of checkpoint inhibitors. The...